BioNTech provides Update on Vaccine Production Status at Marburg Manufacturing Site
March 26, 2021 09:45 ET
|
BioNTech SE
MAINZ, GERMANY, March 26, 2021 (GLOBE NEWSWIRE) — BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the...
Update zur Impfstoffproduktion in BioNTechs Produktionsstätte in Marburg
February 10, 2021 03:00 ET
|
BioNTech SE
MAINZ, Deutschland, 10. Februar 2021 (GLOBE NEWSWIRE) - Wir haben mit dem ersten Schritt der Impfstoffproduktion in unserer Produktionsstätte in Marburg begonnen – der Herstellung der mRNA, dem...
Update on vaccine production at BioNTech’s manufacturing site in Marburg
February 10, 2021 03:00 ET
|
BioNTech SE
MAINZ, GERMANY, February 10, 2021 (GLOBE NEWSWIRE) - We started the manufacturing process at the Marburg facility with the execution of the first step: the production of mRNA, which is the active...
BioNTech übernimmt GMP-Produktionsstätte zur Ausweitung der COVID-19 Impfstoffproduktionskapazitäten im ersten Halbjahr 2021
September 17, 2020 04:00 ET
|
BioNTech SE
Mainz, Deutschland, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Anlage wird eine der größten mRNA-Produktionsstätten in Europa und ist das dritte Werk im Produktionsnetzwerk von BioNTech in...
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
September 17, 2020 04:00 ET
|
BioNTech SE
Mainz, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Facility will become one of the largest mRNA manufacturing sites in Europe and the third site in the BioNTech manufacturing network in...
BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines
May 13, 2020 07:00 ET
|
The Sabin Vaccine Institute
WASHINGTON, D.C. and ROME, Italy, May 13, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and...